Atrial Fibrillation and Diabetes Mellitus. Correlation, Co-existence, and Coagulation Therapy

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2012 Mar 29

PMID 22453912

Citations 2

Authors

B Stratmann

D Tschope

Affiliations

Soon will be listed here.

Abstract

Epidemiological studies have reported on the association between diabetes mellitus (DM) and subsequent risk of atrial fibrillation (AF) with inconsistent results. Individuals with DM present with an increased risk (approximate 40%) of subsequent AF compared with unaffected individuals, but the mechanisms underlying the relationship between DM and AF remains speculative. Both entities share common risk factors and, thus, seem to be closely associated with each other. Obviously, the quality of glycemic control is directly related with the risk for AF; the risk is higher with longer duration of treated diabetes and poorer glycemic control. Future research should identify approaches to reduce the risk of AF in people with diabetes by means of consequent screening and anti-coagulation therapy.

Citing Articles

Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?.

Matta M, Saglietto A, De Salvo P, Bissolino A, Ballatore A, Anselmino M Herz. 2019; 44(3):218-222.

PMID: 30847508 DOI: 10.1007/s00059-019-4794-7.

Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2.

Dzhoyashvili N, Efimenko A, Kochegura T, Kalinina N, Koptelova N, Sukhareva O J Transl Med. 2014; 12:337.

PMID: 25491476 PMC: 4268805. DOI: 10.1186/s12967-014-0337-4.

References

Huxley R, Filion K, Konety S, Alonso A . Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108(1):56-62. PMC: 3181495. DOI: 10.1016/j.amjcard.2011.03.004. View

Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L . High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens. 2001; 19(12):2265-70. DOI: 10.1097/00004872-200112000-00021. View

Jeong J . Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci. 2005; 20(1):26-30. PMC: 2808570. DOI: 10.3346/jkms.2005.20.1.26. View

Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K . Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ J. 2008; 72(6):909-13. DOI: 10.1253/circj.72.909. View

Johansen O, Brustad E, Enger S, Tveit A . Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects. Cardiovasc Diabetol. 2008; 7:28. PMC: 2564913. DOI: 10.1186/1475-2840-7-28. View

Kreuzer J . Update on anti-coagulation in atrial fibrillation. QJM. 2011; 104(9):747-60. PMC: 3158856. DOI: 10.1093/qjmed/hcr107. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology.... Europace. 2006; 8(9):651-745. DOI: 10.1093/europace/eul097. View

Ruigomez A, Johansson S, Wallander M, Rodriguez L . Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002; 55(4):358-63. DOI: 10.1016/s0895-4356(01)00478-4. View

Wilhelmsen L, Rosengren A, Lappas G . Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2002; 250(5):382-9. DOI: 10.1046/j.1365-2796.2001.00902.x. View

10.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

11.

Velagaleti R, Massaro J, Vasan R, Robins S, Kannel W, Levy D . Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009; 120(23):2345-51. PMC: 3600834. DOI: 10.1161/CIRCULATIONAHA.109.830984. View

12.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

13.

Zhou Z, Hu D . An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol. 2008; 18(5):209-16. PMC: 4771592. DOI: 10.2188/jea.je2008021. View

14.

Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K . Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology. 2000; 92(1):21-7. DOI: 10.1159/000006942. View

15.

Dublin S, Glazer N, Smith N, Psaty B, Lumley T, Wiggins K . Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010; 25(8):853-8. PMC: 2896589. DOI: 10.1007/s11606-010-1340-y. View

16.

Krahn A, Manfreda J, Tate R, Mathewson F, Cuddy T . The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98(5):476-84. DOI: 10.1016/S0002-9343(99)80348-9. View

17.

Ruigomez A, Johansson S, Wallander M, Rodriguez L . Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc Disord. 2005; 5:20. PMC: 1185525. DOI: 10.1186/1471-2261-5-20. View

18.

Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon M, Paschke R . Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005; 113(9):534-7. DOI: 10.1055/s-2005-872851. View

19.

Frost L, Hune L, Vestergaard P . Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005; 118(5):489-95. DOI: 10.1016/j.amjmed.2005.01.031. View

20.

Oldgren J, Alings M, Darius H, Diener H, Eikelboom J, Ezekowitz M . Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011; 155(10):660-7, W204. DOI: 10.7326/0003-4819-155-10-201111150-00004. View